A Study to Assess the Efficacy & Safety of Nemolizumab (CD14152) in

See also
Status	Clinical Trial	Phase
Completed	`NCT05038982` - Efficacy of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown Origin	Phase 2
Completed	`NCT00869089` - Safety and Efficacy of CC-10004 for Prurigo Nodularis	Phase 2
Completed	`NCT04501666` - An Efficacy and Safety Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis	Phase 3
Completed	`NCT03181503` - Safety and Efficacy of Nemolizumab in PN	Phase 2
Completed	`NCT03630198` - Pain Outcomes Following Intralesional Corticosteroid Injections	Phase 4
Completed	`NCT04944862` - A Study of CDX-0159 in Patients With Prurigo Nodularis	Phase 1
Completed	`NCT05061693` - A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis	Phase 2
Completed	`NCT03546816` - Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis	Phase 3
Recruiting	`NCT06293053` - A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis	Phase 3
Not yet recruiting	`NCT06201715` - Efficacy and Safety of Tofacitinib in Patients With Prurigo Nodularis	N/A
Completed	`NCT02174419` - Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis	Phase 2/Phase 3
Terminated	`NCT03540160` - Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch)	Phase 3
Recruiting	`NCT06427122` - Effect of EMD Protocol for Urge on Dermatology-specific Quality of Life	N/A
Completed	`NCT03816891` - Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis	Phase 2
Recruiting	`NCT05764161` - A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)	Phase 3
Completed	`NCT02196324` - A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN)	Phase 2
Not yet recruiting	`NCT06424470` - Study on the Treatment of Prurigo Nodularis With Stapokibart Injection	Phase 3
Recruiting	`NCT03576287` - Apremilast as Anti-pruritic Treatment in Patients With Prurigo Nodularis	Phase 1/Phase 2
Completed	`NCT05052983` - A Study to Evaluate the Durability of Response and Safety of Nemolizumab for 24 Weeks in Participants With Prurigo Nodularis	Phase 3
Active, not recruiting	`NCT04204616` - A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)	Phase 3

NCT number	NCT04501679
Study type	Interventional
Source	Galderma R&D
Contact
Status	Completed
Phase	Phase 3
Start date	August 11, 2020
Completion date	March 31, 2022

A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms